Navigation Links
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Date:11/15/2011

otherapy for the treatment of patients with EGFR-expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. The use of Vectibix is not recommended in patients whose tumors have KRAS mutations in codon 12 or 13. In Russia, Japan and Israel, Vectibix is also approved for use in combination with chemotherapy for patients with wild-type KRAS mCRC.

About KRAS

Results from studies performed over the last 25 years indicate that KRAS plays an important role in cell growth regulation. In mCRC, EGFR transmits signals through a set of intracellular proteins. Upon reaching the nucleus, these signals instruct the cancer cell to reproduce and metastasize, leading to cancer progression.(4) Anti-EGFR antibody therapies work by inhibiting the activation of EGFR, thereby inhibiting downstream events that lead to malignant signaling. However, in patients whose tumors harbor a mutated KRAS gene, the KRAS protein is always turned "on," regardless of whether the EGFR has been activated or therapeutically inhibited. KRAS mutations occur in approximately 40 to 50 percent of mCRC patients.(5)(6)

About Vectibix

Vectibix is the first fully human anti-EGFR antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of patients with EGFR-expressing mCRC with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing mCRC is based on PFS. More than half of patients who receive Vectibix monotherapy respond to treatment with an average six month PFS benefit. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased
'/>"/>

SOURCE Amgen Europe GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
(Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
(Date:8/31/2015)... 31, 2015  AMRI (NASDAQ: AMRI ) ... collaboration focused on the development, manufacture and marketing ... ("APIs"). The collaboration combines Saneca,s strength in extracting ... developing and manufacturing controlled substance APIs with AMRI,s ... processes into these facilities. The collaboration will also ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4
... April 28, 2011 There,s a sea change sweeping across the ... do they need to carry bottles of liquid and slow-acting pills ... a car, plane or when watching a 3-D movie. ... in the battle against motion-sickness, allowing people to easily avoid nausea ...
... (NYSE: CVS ) today announced it expects ... business of Universal American on Friday, April 29, 2011. ... shareholders cash consideration of $1.25 billion plus the excess ... Part D business, less Universal American,s outstanding trust preferred ...
Cached Medicine Technology:Zentrip Offers a 'Sea Change' in Stopping the Distress from Motion Sickness 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 3
(Date:8/31/2015)... ... 31, 2015 , ... CareSource, a nonprofit Ohio-based health plan, ... capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and ... have contributed to the company’s rapid growth. As the CareSource business model expands ...
(Date:8/31/2015)... BAY PINES, FL (PRWEB) , ... August 31, 2015 , ... ... accessible, high quality healthcare to Veterans residing across southwest Florida by hiring more doctors ... added to the list of expanded services. , In early July, Dr. Anthony Jabre ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
(Date:8/31/2015)... ... , ... Since 1946, the doctors and staff at Clifton Dental Associates have ... arrives at the office, the staff will make them feel welcome and comfortable. ... create a complete dental treatment plan that is unique to each smile! NJ ...
(Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors ... Table that contains a mathematical formula for modifying an image. The LUT changes every pixel's ... CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or ...
Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2
... 2011 The children most likely to walk or cycle ... and in an economically disadvantaged home, according to survey results ... Roman Pabayo of the University of Montreal Hospital Research Centre ... study is unique in that it follows the same group ...
... SATURDAY, July 2 (HealthDay News) -- Staying hydrated is critical ... have different hydration needs, so you need to assess your ... of Tennessee at Chattanooga. "Sweat rate is very simple ... as possible; exercise for half an hour and don,t drink ...
... News) -- Nausea and vomiting after waking from general anesthesia ... from 122 patients with severe postoperative nausea and vomiting (PONV) ... initially identified 41 genetic targets (single nucleotide polymorphisms -- SNPs) ... them to at least one SNP that was common to ...
... contain baked milk into the diets of children who have ... according to a study conducted at Mount Sinai School of ... the May 23 issue of the Journal of Allergy ... 2 to 17 years old, who were diagnosed with milk ...
... 1 (HealthDay News) -- Increasing daily soluble fiber intake may ... other substances linked to a host of chronic diseases, according ... found just under the skin, visceral fat is located deep ... Researchers at Wake Forest Baptist Medical Center found the way ...
... 1, 2011 Surgery and all its implications can be ... dread sometimes disfiguring scars. Now a UT Southwestern Medical ... that makes scarring virtually invisible yet is just as effective ... with minimally invasive surgery, leave the child with up to ...
Cached Medicine News:Health News:Urban children are healthier commuters than rural teens 2Health News:How to Stay Hydrated in Hot Weather 2Health News:Foods with baked milk may help build tolerance in children with dairy allergies 2Health News:Soluble Fiber Appears Key to Trimming 'Bad Fat' 2Health News:UT Southwestern pediatric urologist develops procedure to eliminate scarring in kidney surgeries 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With tubular ...
Medicine Products: